Excretion Balance, PK and Metabolism of a Single Oral Dos... | NCT04649216

NCT04649216

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Description Module

Label	Type	Description	Intervention Names
Mass Balance	Experimental	Subjects will receive a single oral dose of [14C]PCO371 Oral Solution.	Drug: [14C]PCO371
Absolute Bioavailability and Mass Balance	Experimental	Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of [14C]PCO371 over 10 min, starting 2 h post-oral dose.	Drug: PCO371 Drug: [14C]PCO371

Name	Type	Description	Arm Group Labels	Other Names
PCO371	Drug	PCO371 Capsule	Absolute Bioavailability and Mass Balance

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Mass balance data for [14C]PCO371 Oral solution in urine	Amount of total radioactivity excreted in urine(Ae(urine)) and Ae(urine) expressed as a percentage of the radioactive dose administered (%Ae(urine)), cumulative amount of total radioactivity excreted in urine (CumAe(urine)) and CumAe(urine)expressed as a percentage of the radioactive dose administered (Cum%Ae(urine)) following oral administration of [14C]PCO371 Oral Solution.	1 week
Mass balance data for [14C]PCO371 Oral solution in feces	Amount of total radioactivity excreted in feces(Ae(feces)) and Ae(feces) expressed as a percentage of the radioactive dose administered (%Ae(feces)), cumulative amount of total radioactivity excreted in feces (CumAe(feces)) and CumAe(feces)expressed as a percentage of the radioactive dose administered (Cum%Ae(feces)) following oral administration of [14C]PCO371 Oral Solution.	5 weeks
Mass balance data for [14C]PCO371 Oral solution in urine and feces combined	Amount of total radioactivity excreted in urine and feces combined(Ae(total)) and Ae(total) expressed as a percentage of the radioactive dose administered (%Ae(total)), cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and CumAe(total)expressed as a percentage of the radioactive dose administered (Cum%Ae(total)) following oral administration of [14C]PCO371 Oral Solution.	5 weeks
Absolute bioavailability (F) for PCO371	Time of maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution	1 week

Secondary Outcomes

Measure	Description	Time Frame
Pharmacokinetic data for [14C]PCO371 Oral Solution; Tmax	Time of maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution	1 week
Pharmacokinetic data for [14C]PCO371 Oral Solution; Cmax

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Healthy males
Aged 40 to 60 years inclusive at the time of signing informed consent.
Body mass index (BMI) of 18.5 to 30.0 kg/m2 as measured at screening.
Must be willing and able to communicate and participate in the whole study.
Subjects must have regular bowel movements (i.e. average stool production of >=1 and <=3 stools per day).
Must provide written informed consent.
Must agree to adhere to the contraception requirements.
Subjects must regularly consume 2 or more units of alcohol per week.

Exclusion Criteria:

Subjects who have taken any experimental (non-approved) drug (including placebo) either within 90 days before the administration of the study drug, or 6 times the T1/2 of the experimental drug, whichever is longer.
Subjects who have previously been administered IMP in this study. Subjects are not permitted to be dosed in both Part 1 and Part 2 of the study.
Subjects who have been administered IMP in any 14C-labelled ADME in the last 12 months.
Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years.
No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
Subjects who do not have suitable veins for multiple venipunctures / cannulation as assessed by the investigator or delegate at screening.
Clinically significant abnormal clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator at screening or admission.
Abnormal (outside of reference range) serum calcium or corrected calcium as measured at admission or screening.
Elevated (> 2.5 × upper limit of normal [ULN]) alkaline phosphatase at admission or screening. Subjects with Gilbert's syndrome or elevated (above the ULN) aspartate aminotransferase (AST), ALT or total bilirubin at admission or screening.
Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results.
Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <60 mL/min using the Cockcroft-Gault equation.
Confirmed positive drugs of abuse test result.
History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, immunologic, metabolism, endocrine, neurological or psychiatric disorder, as judged by the investigator, blood dyscrasia, risk factors for osteosarcoma as judged by the investigator.
Evidence or any history of active diseases that might affect calcium, bone metabolism, or calcium-phosphate homeostasis.
Use of anti-coagulants (e.g. heparins, warfarin, and thrombolytic agents), anti-platelet medications (e.g. argatroban and ticlopidine), nonsteroidal anti-inflammatory drugs and aspirin within 2 weeks (or within 6 times the T1/2 of the drug, whichever is longer) prior to study drug administration.
Subjects who have taken any inducers of CYP3A4, P glycoprotein (e.g. St. John's wort), or BCRP within 1 month prior to study drug administration, or taken any inhibitors of CYP3A4, P-glycoprotein, or BCRP (including herbal products, diets, and drinks e.g. tonic water) within 2 weeks prior to study drug administration (or within 6 times the T1/2 of the drugs mentioned above, whichever is longer).